IMMUFLAM – A POTENTIAL THERAPEUTIC APPROACH IN THE TREATMENT OF POST-COVID-19. SHARED OWN EXPERIENCE

Abstract

Abstract Signs and symptoms of illness that persist for more than 12 weeks and are not explained by an alternative diagnosis are most commonly described as persistent Covid-19. The development and severity of Long Covid does not seem to correlate with the nature of the symptoms in the acute phase of the infection. Large health systems in the US and England often offer various therapeutic options to deal with prolonged Covid, including physical therapy, mental health support, but still lack sufficient pharmaceutical options. There is already sufficient scientific data on natural products with immunoregulatory and anti-inflammatory effects. IMUFLAM- belongs to the group of compounds with therapeutic potential against the new respiratory corona virus. Referring to the data from scientific publications and already accumulated clinical experience, we applied Imuflam as part of the therapeutic solutions of patients with Covid-19, after their discharge, with the aim of influencing the long-term health consequences of our patients. The clinical observation covers 30 patients hospitalized during the period from 01.11 to 30.11.2021. in the Gastroenterology Clinic of St. Marina UMBAL, Varna. Patients were drawn into 3 groups of x 10 patients Ist group – applied treatment with Imuflam in a dose regimen of 2x1 caps II-nd group took nutritional supplements without a doctor's prescription (vitamin D, vitamin C, selenium, zinc, vitamin B12). III-th control group. The assessment was carried out on the 15th and 30th day of the application of Imuflam, respectively food supplements without a doctor's prescription. In the first 15 days, no significant differences in clinical complaints were observed in the three groups of patients, which did not apply to the period of 30 days after admission.